Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice


Clinical Trial Description

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy. A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01933958
Study type Observational
Source Bayer
Contact
Status Completed
Phase
Start date September 4, 2013
Completion date October 29, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05385549 - 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk Phase 2
Recruiting NCT05905887 - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor Phase 2
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT01440959 - Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 Phase 2
Completed NCT00718562 - Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib Phase 2
Completed NCT00385203 - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). Phase 2
Completed NCT00137449 - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor Phase 2
Completed NCT00237172 - Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) Phase 2
Terminated NCT04409223 - Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib Phase 3
Active, not recruiting NCT03556384 - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Recruiting NCT04106024 - Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial Phase 2
Completed NCT02171286 - The Oncopanel Pilot (TOP) Study N/A
Completed NCT01114087 - Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility N/A
Recruiting NCT05366816 - ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST Phase 2
Recruiting NCT03602092 - Observational Registry Data on GIST Patients
Recruiting NCT05197933 - Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach N/A
Completed NCT02931929 - MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT Phase 1/Phase 2
Withdrawn NCT05080621 - Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Completed NCT02607332 - Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib Phase 2